Prostacyclin therapy in peripheral arterial disease

Szczeklik, Andrzej; Gryglewski, Ryszard J.; Niżankowski, Rafał; Skawiński, S; Głuszko, Piotr; Korbut, R

doi:10.1016/0049-3848(80)90418-1

Cited by 54 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After flushing, this is usually the most frequent adverse effect in patient studies also (Bergman et al, 1981;Dowd et al, 1982;Olsson, 1980;Pardy et al, 1980;Szczeklik, et al, 1980a;Zusman et at., 1981b). Again, the mechanism is unknown but a similar headache often develops with other vasodilators.…”

Section: Headachementioning

confidence: 99%

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Pickles¹,

O’Grady²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Fifty infusions of epoprostenol (PGI2) were made, usually increasing the infusion rate until adverse effects were encountered. The volunteers were appraised that they might experience headache and facial flushing. 2 Facial flushing, headache, tachycardia and decrease in diastolic blood pressure were seen in almost all subjects. Erythema over the venous infusing site was also encountered in 13 infusions. Less common effects were sudden bradycardia, pallor and sweating-the vagal reflex-(seven times) and chest pain (twice). Other complaints included restlessness, abdominal discomfort, nausea and drowsiness.3 The literature on side effects reported during PGI2 infusion is reviewed and recommendations are made concerning administration of PGI2.

show abstract

Section: Headachementioning

confidence: 99%

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Pickles¹,

O’Grady²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…22 It might be assumed that the combination of different strategies to treat PAD, such as the vasodilator action of prostacyclin combined with therapeutic angiogenesis, would be useful to stimulate collateral formation, because prostacyclins are widely used for the treatment of PAD. 23,24 An alternative idea is to achieve the optimal conditions for plasmid DNA transfer into skeletal muscle as follows: (1) increase the injection volume of plasmid DNA, (2) change the solution in which plasmid DNA is dissolved, and (3) apply hyperbaric oxygen (HBO) therapy with plasmid DNA.…”

mentioning

confidence: 99%

Enhanced Therapeutic Angiogenesis by Cotransfection of Prostacyclin Synthase Gene or Optimization of Intramuscular Injection of Naked Plasmid DNA

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Up until now several clinical studies have been published on therapeutic efficacy of PGI 2 in advanced PVD although most of them were uncontrolled (Szczeklik et al 1979(Szczeklik et al , 1980Pardy et al 1980;Machin etal. 1981;Olsson and Nilsson 1981).…”

Section: Discussionmentioning

confidence: 98%

Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: A placebo-controlled cross-over study

et al. 1984

View full text Add to dashboard Cite

Twelve patients (age 33-77 years, mean age 68.4 years) with peripheral vascular disease (PVD) stage III-IV received continuous intravenous infusions of 5 ng prostacyclin (PGI2)/kg/min and physiological saline for 7 days. The administration was randomized and double-blind with an interval of 7 days between the infusions. During PGI2 infusion systolic blood pressure fell significantly from 147.8 +/- 4.8 mm Hg to 140.6 +/- 4.0 mm Hg (P less than 0.01) and returned to 144.5 +/- 4.9 mm Hg post infusion. Transcutaneous pO2 (tcpO2) measured on the instep of the affected limb increased significantly by 8.9 +/- 3.8 Torr during PGI2 infusion and remained elevated during the subsequent week. A significant reduction of pain was observed from the 5th day of PGI2 infusion, lasting for at least the following observation period. Platelet cAMP increased from 18.8 +/- 1.5 pmol/10(8) platelets to 24.7 +/- 1.6 pmol/10(8) platelets on the 3rd day of PGI2 infusion (P less than 0.01). Spontaneous platelet aggregation was also significantly reduced during PGI2 infusion. However, 7 days after the infusion thromboxane B2 (TXB2) in plasma and spontaneous platelet aggregation significantly increased in comparison with the preinfusion values, indicating a rebound phenomenon. The clinical outcome was favorable in 9 of 12 patients, was unchanged in two patients, while progressing to limb amputation in one patient.

show abstract

Prostacyclin therapy in peripheral arterial disease

Cited by 54 publications

References 9 publications

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Enhanced Therapeutic Angiogenesis by Cotransfection of Prostacyclin Synthase Gene or Optimization of Intramuscular Injection of Naked Plasmid DNA

Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: A placebo-controlled cross-over study

Contact Info

Product

Resources

About